At any time, up to half of men with diabetes may be experiencing erectile dysfunction (ED), according to Aruna V. Sarma, PhD, MHA. Dr. Sarma and Deepak K. Jumani, MBBS, FCGP, discussed ED and male sexual dysfunction in diabetes patients during a Scientific Sessions mini-symposium.

During the Scientific Sessions, an expert panel of cardiologists and endocrinologists provided an update on heart failure for diabetologists. Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, reported that 50% to 80% of people with diabetes die of cardiovascular disease.

During a Virtual 80th Scientific Sessions presentation, Domenico Accili, MD, delivered “a message of hope” for the future of type 2 diabetes treatment. “From what we’ve learned, we think that we can reverse beta-cell failure in a mechanistic manner. This should lead to truly disease-modifying interventions for patients with type 2 diabetes,” he said.

The coronavirus pandemic and the high number of COVID-19 patients with diabetes have heightened interest in real-time continuous glucose monitoring (CGM). “The ability to have remote access to data and time-in-range data when we’re doing telehealth consultations during the COVID pandemic has been fabulous. We may not be going back to face-to-face as often as…

Hypoglycemia is a major barrier to achieving glucose targets that prevent diabetes complications, but there’s no consensus whether 54 mg/dL or 70 mg/dL is the best standard for hypoglycemia in clinical trials. Simon R. Heller MD, FRCP, and Aaron J. Kowalski, PhD, examined the value of the two standards during a Scientific Sessions symposium.

Findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, one of the newer sodium-glucose cotransporter 2 (SGLT2) inhibitors, indicate that the drug does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes. The findings were presented by a panel of trial investigators, including…

Results from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) showed that dapagliflozin, an SGLT2 inhibitor, reduced the incidence of type 2 diabetes by 32% in patients with heart failure but without diabetes at baseline. “While the major…

Bruce A. Buckingham, MD, and three other experts reviewed results from four new clinical trials examining the next generation of automated insulin delivery systems for type 1 diabetes patients during the Scientific Sessions. New technology holds promise for easing the lifestyle complications of type 1 diabetes by improving glycemic control, particularly overnight, Dr. Buckingham said.

Several researchers from the Diabetes Prevention Program Outcomes Study (DPPOS) shared new data on clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program study during the Scientific Sessions. DPPOS Chair David M. Nathan, MD, said that while the benefits of the original interventions have decreased over time, both the metformin and…

Investigators from The Environmental Determinants of Diabetes in the Young (TEDDY) study presented the latest results from the ongoing study during the Scientific Sessions. TEDDY Co-Chair Marian Rewers, MD, PhD, reviewed research into genetic and clinical markers that indicates that screening for islet autoimmunity in high-risk youth should start in the first two years of…